Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats

Farrag, S.M.; Hamzawy, Mohamed A.; El-Yamany, Mohammed F.; Saad, Marina; Nassar, Natasha

doi:10.1016/j.lfs.2018.04.034

Cited by 12 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once CoQ10 is lacking, different oxidative respiratory chain functions in the mitochondria of the cell become impaired, and the oxygen-free radicals increased, which produce liver damage and increase the ALT and AST levels. CoQ10 supplementation can be used to maintain the integrity of cell structure and function, promote the repair of liver cells, and thus have a certain protective effect on the liver damage [23,24]. On the other hand, CoQ10 can also reduce the increase of intracellular calcium concentration caused by statin lipid-lowering drugs, prevent Ca 2+ influx, and reduce liver cell damage caused by intracellular Ca 2+ overload [25].…”

Section: Side Effectsmentioning

confidence: 99%

The Efficacy of Coenzyme Q10 in Combination With Atorvastatin on Coronary Heart Disease

Wang¹

2020

FARMACIA

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of coenzyme Q10 (CoQ10) in combination with atorvastatin on coronary heart disease (CHD). In this study there were included 84 patients with CHD and divided into two groups, a control group (42 patients), treated with atorvastatin and an experimental group (42 patients) that received atorvastatin and CoQ10. CoQ10 levels, transaminase activities (ALT and AST), blood lipid, cardiac function, and hemodynamic, were measured and evaluated before the treatment and 3 months after the treatment. Both treatments were safe and effective in the clinical management if lipidic imbalance in CHD, but the experimental group had better therapeutic effects. The CoQ10 level in the experimental group increased after the treatment (p < 0.05), while in the control group decreased significantly (p < 0.05). ALT and AST levels did not changed significantly after the treatment in the experimental group, while in the control group, it was observed a significant increase (p < 0.05). After treatment, the left ventricular diastolic function of the experimental group was improved significantly (p < 0.05). Meanwhile, the left ventricular diastolic function of the control group was also improved to some extent, but the difference was not statistically significant (p > 0.05). In conclusion, CoQ10 supplementation could avoid the increase of transaminases caused by atorvastatin, and could enhance the lipid-lowering effect of atorvastatin and improve the cardiac function effectively. RezumatScopul acestui studiu a fost evaluarea eficacității coenzimei Q10 (CoQ10) în combinație cu atorvastatina în bolile coronariene (CHD). Au fost incluși 84 de pacienți cu CHD, împărțiți în două grupuri, control (42 de pacienți), grupul tratat cu atorvastatină și un grup experimental (42 de pacienți) care a primit atorvastatină și CoQ10. Nivelurile CoQ10, activitatea transaminazelor (ALT și AST), a lipidelor plasmatice, funcția cardiacă și hemodinamica au fost evaluate înainte de tratament și după 3 luni. Ambele terapii au fost sigure și eficiente în managementul clinic al dezechilibrului lipidic în CHD, dar grupul experimental a prezentat efecte terapeutice superioare. Nivelul CoQ10 în grupul experimental a crescut după tratament (p < 0,05), în timp ce în grupul martor a scăzut semnificativ (p < 0,05). Nivelurile ALT și AST nu s-au modificat semnificativ după tratament în grupul experimental, în timp ce în grupul martor s-a observat o creștere semnificativă (p < 0,05). După tratament, funcția diastolică a ventriculului stâng în grupul experimental a fost îmbunătățită. Funcția diastolică a ventriculului stâng în grupul martor a fost, de asemenea, îmbunătățită. În concluzie, suplimentarea cu CoQ10 ar putea evita creșterea transaminazelor în terapia cu atorvastatină, și ar putea îmbunătăți profilul lipidic și funcția cardiacă.

show abstract

Section: Side Effectsmentioning

confidence: 99%

The Efficacy of Coenzyme Q10 in Combination With Atorvastatin on Coronary Heart Disease

Wang¹

2020

FARMACIA

View full text Add to dashboard Cite

show abstract

“…Moreover, atorvastatin (ATV) has been preferred over other satins initially due to its effective hypolipidemic effect. So it is widely used as a positive control to lower elevated lipid levels; in studies the dose of ATV for rats ranges from 2.08 to 20 mg/kg/day, but the most commonly used effective dose is 10 mg/kg/day [ 4 – 6 ]. However, statins cannot be applied to all populations worldwide due to side effects, whereas in certain cases their efficacy in lowering cholesterol level is not adequate [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV‐1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High‐Fat Diet Rat Model

Ding

Kang

Tong

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Lipid metabolism disorder is a common metabolic disorder characterized by abnormal lipid levels in blood. Erchen decoction (ECD) is a traditional Chinese medicine prescription, which is used for the treatment of diseases caused by retention of phlegm dampness. It has been reported to ameliorate the disorder of lipid metabolism. The aim of the present study was to investigate the effects and underlying mechanisms of ECD in lipid metabolism disorder induced by a high-fat diet (HFD) in rats. ECD (4.35g/kg/d) and atorvastatin (10mg/kg/d, positive control) were orally administered to HFD-fed rats for four weeks. The parameters, food, water consumption, body weight, body length, liver, and visceral fat weight and the content of serum lipids and lipid transporters were assessed. The effects of ECD on the mRNA and protein expression levels of lipid transport factors were measured by real-time PCR and western blotting. The present study demonstrated that ECD improved the disorders of serum lipid and lipid transporters in HFD-fed rats, TG (0.70±0.08 mmol/L, p<0.01), LDL-C (1.50±0.19 mmol/L, p<0.01), LDL (1.38±0.21 mmol/L, p<0.05), and oxLDL (1.77±0.39 ng/mL, p<0.05) were downregulated, while HDL-C (0.87±0.13 mmol/L, p<0.01), FFA (0.62±0.13 mmol/L, p<0.05), HDL (38.8±4.0 mg/dL, p<0.05), and CETP (903.6±120.0 ng/mL, p<0.05) were upregulated. But ECD obviously had no effects on the indices food/water/energy intake, body/tissue (liver and fat) weight, and BMI (p>0.05). Concomitantly, ECD reversed the abnormal expressions of those lipid transport factors in the liver and visceral fat.

show abstract

“…The ALT levels of animals treated with the MS-II (1:0.75) formulation were not significantly different ( p < 0.05) to those of the control group. This treatment had an advantage over EZ-RM due to the significant decrease in TC and lipid parameters, and its lower AST and ALT levels could imply fewer adverse effects on muscles and liver than in the EZ-RM and HFD groups [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

Improvement in the Oral Bioavailability and Efficacy of New Ezetimibe Formulations—Comparative Study of a Solid Dispersion and Different Micellar Systems

et al. 2020

View full text Add to dashboard Cite

Ezetimibe (EZ) is a poorly water-soluble drug with low bioavailability. Strategies such as solid dispersions (SD) and micellar systems (MS) were developed to identify the most effective drug delivery formulations with the highest oral bioavailability, and to improve their lipid-lowering effect. The EZ formulations were prepared with different proportions of Kolliphor® RH40 as a surfactant (1:0.25, 1:0.5 and 1:0.75) and croscarmellose as a hydrophilic carrier. These excipients, and the addition of microcrystalline cellulose during the production process, led to significant improvements in the dissolution profiles of MS. Powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM) revealed an amorphous form of ezetimibe with different semicrystalline states of microcrystalline cellulose for MS-I (1:0.75) and MS-II (1:0.75). Pharmacokinetic analysis after administration of MS-II (1:0.75) demonstrated a 173.86% increase in maximum plasma concentration (Cmax) and a 142.99% increase in oral bioavailability compared to EZ raw material (EZ-RM). Efficacy studies with the micellar system MS-II (1:0.75) in rats with hyperlipidemia showed that total cholesterol, triglycerides and high-density lipoprotein were reduced to normal levels and revealed improvements in low-density lipoprotein, aspartate and alanine aminotransferase. The improvement in the dissolution rate with micellar systems increases bioavailability and enhances the anti-hyperlipidemic effect of EZ.

show abstract

Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats

Cited by 12 publications

References 53 publications

The Efficacy of Coenzyme Q10 in Combination With Atorvastatin on Coronary Heart Disease

The Efficacy of Coenzyme Q10 in Combination With Atorvastatin on Coronary Heart Disease

Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV‐1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High‐Fat Diet Rat Model

Improvement in the Oral Bioavailability and Efficacy of New Ezetimibe Formulations—Comparative Study of a Solid Dispersion and Different Micellar Systems

Contact Info

Product

Resources

About